Therefore, a negative effect of VEGF reduction on soft and hard tissue healing is relevant to MRONJ pathogenesis and can explain disease occurrence exclusively in the ZOL, but not in the DEX groups, as well as in patients taking anti-VEGF or BPs. This evidence concerns the gene VEGFA and Bartsocas-Papas syndrome 1.